Time & location: 11:00 EST, Virtual
Join Dr. Laia Montoliu-Gaya, Assistant Professor from the University of Gothenburg, as she discusses recent advancements in Simoa® assays, designed to aid Alzheimer’s disease diagnosis and staging and expand access to broader populations.
Gain insight into the current state of the field, with a focus on Simoa assay development and application, as well as the technical innovations and strategic approaches scientists are using to drive progress.
Key learning objectives
- Explore the recent developments in Simoa immunoassays
- Learn about innovative applications and sample collection systems
- Explore the application of both established and new Simoa biomarkers in Alzheimer’s disease
- Learn more about expanding access to blood biomarkers for broader populations
Who should attend?
-
- Neurology department heads and clinical directors
- Research directors and principal investigators
- Laboratory managers and diagnostics supervisors
- Biotech and pharma R&D executives
- Product development managers in medical diagnostics
- Senior researchers in neurodegenerative disease
- Clinical trial managers and coordinators
- University research department: researchers, leads, chairs, and program directors
Speaker
Dr. Laia Montoliu-GayaAssistant Professor, University of Gothenburg, Sweden
Dr. Laia Montoliu-Gaya, Assistant Professor at the University of Gothenburg, Sweden, is the inventor of a unique mass spectrometry method to detect tau species in blood for the diagnosis of Alzheimer’s disease. In addition, she is a co-inventor of a digital immunoassay for the quantification of p-tau205 in human biofluid and has also performed extensive work in diagnosing Alzheimer’s disease in individuals with Down syndrome.
Related Posts
Underdiagnosis of Alzheimer’s disease pathology in patients with cardiovascular disease
Decoding Neurodegeneration: High-plex Spatial Proteomics Reveal Distinct Cell Phenotypes and Pathological Signatures in Parkinson’s and Alzheimer’s Disease
In this webinar, Dr. Birgitt Schuele, Associate Professor (Research) of Pathology at Stanford University, showcases how ultrahigh-plex spatial proteomics is being used to uncover distinct cell phenotypes and pathological signatures…
Understanding the Brain: Advancing Neurodegeneration Research with Ultrahigh-Plex Spatial Proteomics
In this webinar, learn how ultrahigh-plex spatial phenotyping has been applied to neurodegenerative disease research.
p-Tau 205 and p-Tau 212: Emerging Biomarkers for Alzheimer’s Disease Research
Spatial Awareness: AI-powered Profiling of Trillions of Immune Cell Distribution Data Points Reveals Key Predictors of Cancer Recurrence Risk
This webinar highlights a groundbreaking study recently published as a Nature cover story (April 2025). Dr. Joe Yeong will describe how a pre-designed analytical framework—driven by well-defined clinical and scientific…
Multimodal Single-Cell Spatial Transcriptomics and Proteomics to Uncover the Biological Processes Driving Immunotherapy Response and Resistance in Renal Cancer
In this webinar, Dr. Anne-Laure Cattin from the Cancer Dynamics Laboratory at The Francis Crick Institute in London, will share her research on kidney cancer, focusing on the integration of…
Tertiary Lymphoid Structures in Cancer Immunotherapy: Insights and Perspectives
Tertiary lymphoid structures (TLS) have emerged as critical components of the tumor microenvironment, influencing immune responses and clinical outcomes in cancer.
